expensive and impractical, and consequently these techniques are not routinely performed in clinical research or practice. 3, 4 Clinicians must therefore rely on eGFR to identify CKD and evaluate renal function. The most widely used clinical laboratory reported eGFR equations are based on standardized serum creatinine assays and include the MDRD creatinine equation, 5 and the CKD-EPI Collaboration creatinine equation (CKD-EPI cr ). 6 In general, creatinine-based equations for GFR can be confounded by muscle mass, the main determinant of creatinine generation. 4 Although MDRD and CKD-EPI cr include age as a surrogate marker, agerelated reductions in muscle mass may lead to biased, imprecise, and inaccurate estimates of GFR in older adults. 7, 8 The uncertainty around using creatininebased eGFR in older adults has led to an interest in use of alternative filtration markers for clinical evaluation of kidney function.
Cystatin C is an endogenous 13-kDa protein that is produced at a stable rate by all nucleated cells and is filtered by the glomeruli and reabsorbed by epithelial cells of the proximal tubule. 9 Its production is less confounded by ethnicity, age, or sex compared with creatinine. 10, 11 The most widely used cystatin C-based equations include the CKD-EPI cystatin C equation (CKD-EPI cys ) and the CKD-EPI creatinine-cystatin C equation (CKD-EPI cr-cys ). 12 Use of cystatin C in combination with creatinine has been shown to improve the accuracy of eGFR compared with using either marker alone, 12, 13 and it has also demonstrated a stronger association between decreased eGFR and subsequent risk of death, and cardiovascular and kidney disease outcomes. 14, 15 However, use of eGFR by creatinine and cystatin C for clinical decision making, such as staging of early CKD, drug dosing, and prediction of adverse outcomes remains suboptimal due to a lack of precision and accuracy.
b2M is a low molecular weight protein component of class I major histocompatibility molecules and is found on the surface of nucleated cells; it is filtered by the glomerulus and retained in the blood as GFR declines. 16 Similar to cystatin C, b2M has been shown to be less affected by age, sex, and ethnicity and has stronger associations with death, cardiovascular disease, and kidney disease outcomes compared with creatinine. 10, 17 An equation has recently been developed for eGFR by b2M, 18 but it has not been extensively evaluated.
A lack of precision and accuracy of eGFR may be of particular concern in older adults with longstanding diabetes duration who are at elevated risk of developing diabetic nephropathy, 19 and who have additional eGFR confounders such as hyperglycemia. 20 Even though diabetes is the leading cause of CKD, end-stage renal disease (ESRD), and dialysis in the western world, 21 the accuracy of eGFR equations to assess renal function in those with longstanding T1D has not been evaluated. Studies to date that have evaluated the accuracy of CKD-EPI cr , CKD-EPI cys , and CKD-EPI cr-cys in older adults have been limited to elderly individuals without T1D, [22] [23] [24] [25] [26] [27] and the accuracy of b2M has not been evaluated in older adults or in T1D. Accordingly, our aim was to evaluate the performance of eGFR by serum creatinine, cystatin C, and b2M compared with mGFR by inulin clearance in older adults with and without T1D.
METHODS

Study Population
This was a cross-sectional study involving patients who were recruited for the second phase of the Canadian Study of Longevity in Type 1 Diabetes. 28 Between February 2015 and September 2016, a total of 75 participants with $50 years of T1D and 75 age-and sexmatched nondiabetic controls underwent extensive phenotyping procedures over the course of 2 clinical visits set 2 to 4 weeks apart. Participants with T1D were recruited from the nationwide registry of approximately 450 Canadians with $50 years of T1D established during the first phase of the study, [29] [30] [31] [32] [33] and nondiabetic controls were friends or family members of T1D participants, or were recruited through community advertisement. Search criteria for the second phase included residence in the Greater Toronto Area (e.g., proximity to the University Health Network and Mount Sinai Hospital in Toronto, Ontario, Canada), or a willingness to travel for 2 requisite study days. Inclusion criteria for T1D participants was $50 years of T1D duration, and inclusion criteria for nondiabetic controls was any race and sex-matched 1:1 within 5 years of age of a T1D participant. Inclusion criteria common to both nondiabetic controls and T1D participants was the ability to understand and cooperate with study procedures. Exclusion criteria for controls was the presence of diabetes mellitus. Exclusion criteria common to both nondiabetic controls and T1D participants were specific to phenotyping procedures not discussed in this article and included (i) any current eye infection, corneal damage, severe movement disorder, or proparacaine allergy to preclude safe corneal confocal microscopy examination; and (ii) blood pressure >140/90 mm Hg to preclude angiotensin II infusion procedures. All participants provided written informed consent, and the study and its procedures were approved by the institutional ethics board at the University Health Network and Mount Sinai Hospital in Toronto, ON, Canada.
Laboratory Methods mGFR was determined by the mean of 2 plasma inulin clearances and was expressed per 1.73 m 2 body surface area, 34 and details of this procedure can be found in the Supplementary Methods. Creatinine was measured using the Abbott Architect chemistry analyzer using manufacturer's reagents with the Modified Jaffe Kinetic method (coefficients of variation of 2.8% and 1.8% at 1.4 and 6.6 mg/dl, respectively), which is traceable to National Institute Standardized Technology creatinine standard reference material 967. Cystatin C was measured on an immunoturbidimetric assay kit (Kamiya Biomedical Company, Seattle, WA) (coefficient of variation 6.5%). Cystatin C values were adjusted so that they could be traceable to the eGFR Equations eGFR by creatinine and cystatin C was calculated from equations developed by the MDRD and CKD-EPI groups. 5, 6, 12 eGFR by b2M was calculated using the equation developed by Inker et al. 18 Supplementary Table S1 presents the equations in detail.
Statistical Analyses
All analyses were performed using SAS 9.4 for Windows (SAS Institute, Cary, NC). An a-level of 0.05 (2-tailed) was used for tests of statistical significance. Comparisons of the clinical characteristics between controls and T1D were made using Student t-test, the Wilcoxon rank-sum test, or the c 2 test, depending on variable distribution. Correlation and agreement between mGFR and eGFR were assessed using the method of Bland and Altman. 37 Spearman's rank correlation coefficients (r s ), the mean difference, and the 95% limits of agreement (2.5th and 97.5th percentiles of the mean difference) were used to assess correlation, magnitude, and direction of agreement between eGFR and mGFR.
Equation Performance
The performance of eGFR was assessed using metrics for bias, precision, and inaccuracy. 38 Bias was assessed using the mean difference between eGFR and mGFR (eGFR À mGFR) and precision was assessed using the SD of the difference. Relative bias and relative precision were assessed using the mean and SD of the % difference, respectively; higher SDs represented lower precision. Accuracy was assessed using 1ÀP 30 (the proportion of eGFR that differed by more than 30% of mGFR) and 1ÀP 20 (the proportion of eGFR that differed by more than 20% of mGFR); higher percentages represented lower accuracy. The 95% confidence intervals around bias, precision, relative bias, relative precision, 1ÀP 30 , and 1ÀP 20 were calculated using the bootstrap method (2000 bootstraps, with replacement). In addition to control and T1D subgroups, other subgroups were defined from the total study population according to age range (<60, 60-69, $70 years), sex (male or female), body mass index range (<25, 25-29, $30 kg/ m 2 ), diabetes duration (50-52, 53-56, $57 years) in those with T1D, and mGFR range (60-89, 90-119, $120 ml/min per 1.73 m 2 ). Bias, precision, and accuracy metrics were used to assess eGFR performance in the study population and within subgroups.
The significance of differences between equations was determined with the use of a paired t-test for bias, a 2-tailed F-test for precision, and the McNemar test for 1ÀP 30 and 1ÀP 20 . The significance of differences between subgroups were determined with the use of analysis of variance or Student t-test for bias, a 2-tailed F-test for precision, and the c 2 test for 1ÀP 30 and 1ÀP 20 .
RESULTS
Characteristics of the Study Population
Among eligible participants enrolled in the Canadian Study of Longevity in Type 1 Diabetes, 66 of 75 (88%) participants with $50 years of T1D and 73 of 75 (97%) age-and sex-matched nondiabetic controls underwent both measures: mGFR and eGFR. Clinical characteristics of the 139 participants are shown in Table 1 . Controls and patients with T1D were similar age (65 AE 8 vs. 66 AE 7 years, P ¼ 0.54) and the proportion of participants who were female sex was similar (56% vs. 55%, P ¼ 0.85). T1D participants had mean HbA1c of 7.4 AE 0.8% (57 AE 8.7 mmol/mol) and had median (interquartile range) diabetes duration of 54 (52,58) years. Serum creatinine was lower in controls compared with patients with T1D (0.7 AE 0.1 vs. 0.8 AE 0.2 mg/dl, P ¼ 0.048). Serum cystatin C was similar between controls and patients with T1D (1.1 AE 0.3 vs. 1.1 AE 0.3 mg/l, P ¼ 0.91).
Serum b2M was similar between controls and patients with T1D (1.6 AE 0.5 vs. 1.5 AE 0.8 mg/l, P ¼ 0.68).
GFR Measures and Classification of GFR Range Subgroups
Mean measures of GFR and the proportion of participants in GFR range subgroups (<60, 60-89, 90-119, $120 ml/min per 1.73 m 2 ) are displayed in Table 2 . There were no differences in mean GFR between controls versus patients with T1D, except for CKD-EPI cr ( of participants were misclassified into a different GFR range subgroup by MDRD, 50% were misclassified by CKD-EPI cr , 78% were misclassified by CKD-EPI cys , 70% were misclassified by CKD-EPI cr-cys , and 60% were misclassified by b2M. Figure 1 (Scatter and Bland-Altman plots) demonstrates the correlation and agreement for each equation compared with mGFR. On inspection of these plots, all equations had weak-moderate positive relationships with mGFR and agreement between eGFR and mGFR was poor. The corresponding performance metrics of each equation in the study population and in the control and T1D subgroups are presented in Table 3 . Creatinine-and cystatin C-based equations significantly underestimated mGFR with bias À14.9 ml/min per 1.73 m 2 for MDRD, À15.9 ml/min per 1.73 m 2 for CKD-EPI cr , À30.3 ml/min per 1.73 m 2 for CKD-EPI cys , and À23.2 ml/min per 1.73 m 2 for CKD-EPI cr-cys (P < 0.001 for each equation compared with mGFR). b2M
Comparisons of Agreement and Equation Performance
had bias of 1.9 ml/min per 1.73 m 2 (P ¼ 0.61). Bias was greater in cystatin C-based eGFR compared with equations that did not include cystatin C, and was greatest for CKD-EPI cys (P < 0.001 for comparison with each equation). Precision was similar between creatinine-and cystatin C-based equations, but was lowest for b2M (43.5 ml/min per 1.73 m 2 , P < 0.001 for comparison with each equation). Accuracy (1ÀP 20 ) was highest for eGFR by creatinine (MDRD 32.4%, CKD-EPI cr 37.4%), was lower for CKD-EPI cr-cys (52.5%) and (43) 33 (45) 27 (41) 90-119, n (%) 33 (24) 15 (21) 21 (31)
CKD-EPI creatinine-cystatin C equation 30 . No differences in performance metrics were observed between controls and T1D for creatinine-or cystatin C-based eGFR. Compared with controls, patients with T1D had a greater magnitude for bias (À7.2 vs. 11.6 ml/min per 1.73 m 2 , P ¼ 0.014), lower precision (25.4 vs. 55.5 ml/min per 1.73 m 2 , P < 0.001), and lower accuracy (1ÀP 20 35.6% vs. 71.2%, P < 0.001) for b2M.
Subgroup Comparisons
We evaluated the performance of eGFR in subgroups based on demographic and clinical characteristics. The bias and 95% confidence interval between eGFR and mGFR according to age range, sex, body mass index range, T1D duration, and mGFR range are displayed in Figure 2 ; the corresponding quantitative values for each subgroup are presented in Supplementary  Table S2 . Bias was greater in older age groups (<60, 60-69, $70 years) for CKD-EPI cys and CKD-EPI cr-cys and the accuracy (1ÀP 20 ) was lower in older age groups for CKD-EPI cys (53%, 71%, 80%, P ¼ 0.039) and CKD-EPI cr-cys (35%, 49%, 61%, P ¼ 0.042). Bias was greater in women versus men for MDRD, CKD-EPI cys , and CKD-EPI cr-cys and the accuracy (1ÀP 20 ) was lower in women versus men for MDRD (39% vs. 22%, P ¼ 0.046), CKD-EPI cys (79% vs. 56%, P ¼ 0.004), and CKD-EPI cr-cys (61% vs. 42%, P ¼ 0.030). The bias across mGFR 60-89, 90-119, and $120 ml/min per 1.73 m 2 subgroups was greater for all equations; accuracy (1ÀP 20 ) was lower at higher ranges of mGFR for MDRD (16%, 26%, 65%, P < 0.001), CKD-EPI cr (13%, 26%, 77%, P < 0.001), CKD-EPI cys (52%, 65%, 83%, P < 0.001), and CKD-EPI cr-cys (35%, 49%, 77%, P < 0.001).
CONCLUSION
Accurate estimation of GFR is an important tool for clinicians to routinely identify kidney disease, to monitor changes in renal function, to estimate prognosis for ESRD, and for selection of appropriate use and dosing of pharmacotherapies. We found that in older adults with and without T1D, who had preserved renal function according to mGFR, eGFR by serum creatinine, cystatin C, and b2M did not accurately ascertain GFR. Cystatin C-based eGFR performed worse than creatinine-based eGFR and had lower performance in older subgroups, and the combination of both creatinine and cystatin C did not outperform creatinine alone. b2M was the least biased, but was the least precise and had lower performance in patients with T1D. In addition, all equations had lower performance at higher ranges of mGFR. Due to poor performance, eGFR by creatinine was associated with 6% falsepositive rate for stage 3 CKD (mGFR <60 ml/min per 1.73 m 2 ), eGFR by cystatin C was associated with 30%
false-positive rate, eGFR by b2M was associated with 9% false-positive rate, and all equations had more than 50% misclassification of GFR range subgroups overall.
Creatinine is the most widely used and readily available endogenous filtration marker to estimate GFR in research and clinical settings. 2, 6 Age-related reductions in muscle mass have long been hypothesized to reduce serum creatinine concentrations in older adults. 8 This could result in systematic bias of mGFR by creatinine-based eGFR and therefore misclassify CKD in older patients. Consequently, serum cystatin C, an endogenous filtration marker that is not confounded by muscle mass, has been hypothesized to be the preferred filtration marker in older adults. In external validation cohorts of younger adults, 1, 12 eGFR by combination of cystatin C and creatinine has been shown to be more accurate than using either marker alone. Interestingly, in our study population of older adults with and without T1D, and without CKD, eGFR by cystatin C performed worse than creatinine, had lower performance in older subgroups, and the combination of cystatin C and creatinine had lower performance than creatinine alone. These findings suggest that eGFR by creatinine, although itself associated with limited accuracy, may provide benefit over cystatin C in older adults with preserved renal function. The finding that cystatin C did not improve on creatininebased eGFR is consistent with one recent study that evaluated eGFR performance in elderly Malaysian adults ($65 years old) who had a mean mGFR of 41 AE 19 ml/min per 1.73 m 2 according to 51 chromium EDTA. 39 However, the findings of both our study and the Malaysian study are inconsistent with results from a recent study of Icelandic adults aged 74 to 93 years who had a mean mGFR of 62 AE 16 ml/min per 1.73 m 2 by plasma clearance of iohexol. 40 In this study, cystatin C improved on all creatinine-based equations. One other key study determined that eGFR by combination , and creatinine-cystatin C (d 2 ) equations, and the b2M equation (e 2 ); points above or below zero on the y-axis represent overestimation and underestimation of mGFR by eGFR, respectively. The dotted lines correspond to, from top to bottom, the 97.5th percentile of differences, the mean difference (bias metric), and the 2.5th percentile of differences.
of cystatin C and creatinine performed better than eGFR by either marker alone in 805 adults with mean age 80 AE 4 years and mean mGFR of 62.4 AE 16.5 ml/min per 1.73 m 2 according to plasma clearance of iohexol.
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These findings are inconsistent with our study, the Malaysian study, and the Icelandic study. Overall, the poor performance of eGFR by creatinine and cystatin C in the present study, and the inconsistency of findings across multiple studies is problematic because these equations are commonly applied to this population and inaccurate estimates of CKD prevalence and renal function can lead to disparities in treatment decisions, incorrect selection of interventions, and unnecessary health care costs. 41, 42 Our study was able to provide a novel evaluation of eGFR by b2M, an equation for which accuracy had yet to be evaluated in older adults or in patients with T1D. GFR estimated by b2M had the lowest magnitude of bias but was highly imprecise when compared with eGFR by creatinine and cystatin C. We also found that performance of b2M was lower in patients with T1D compared with nondiabetic controls, which should be confirmed in younger adults with T1D. The identification of filtration and nonfiltration factors that may be associated with imprecision of eGFR by b2M is needed, specifically in T1D.
Annual reports from the US Renal Data System have confirmed that diabetes is the leading cause of CKD and ESRD, and that the age/sex/race-adjusted prevalence of ESRD has risen over time, with steeper increases among older adults. 21 Given that the general population is aging, 43 and prevalence of diabetes is increasing, 44 it is important to accurately identify kidney disease in older adults, Accuracy was calculated as the proportion of eGFR that differed from mGFR by more than 30% (1ÀP 30 ) and the proportion that differed by more than 20% (1ÀP 20 ).
b2M, b2-microgobulin; CI, confidence interval; CKD-EPI, Chronic Kidney Disease-Epidemiology; MDRD, Modification of Diet and Renal Disease; T1D, type 1 diabetes.
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especially in those with diabetes. Findings from the DCCT/ EDIC study have demonstrated that eGFR may not accurately reflect changes over time in GFR in those with T1D. 45 Similarly, the significant underestimation, imprecision, and inaccuracy found in the present study has implications on the ability eGFR to accurately detect CKD in older adults with T1D. Although the poor performance of eGFR was nondifferential between older adults with and without T1D, except for b2M in which performance was lower in T1D, the inaccurate and imprecise ascertainment of eGFR in those with longstanding T1D is highly concerning because this subgroup of the population has an amplified risk for the development of CKD that requires accurate GFR estimation methods that are not susceptible to misclassification. 19 Rapid GFR decline has been established as one of the earlier phenotypes of CKD, and has been strongly associated to risk of ESRD, and cardiovascular and allcause mortality. [46] [47] [48] Ideally, eGFR equations should be able to detect early declines in GFR when interventions may be most effective in preserving renal structure and function. 49 The prevailing lack of precision and accuracy of eGFR when GFR >60 ml/min per 1.73 m 2 may hinder the ability to accurately detect these early changes, although inaccuracy in cross-sectional measures may not translate to inaccuracies in the change in values over time. In this study, we found greater bias at higher ranges of mGFR (60-89, 90-119, $120 ml/min per 1.73 m 2 ) for all 5 equations. This finding highlights the limitations of current eGFR equations for the crosssectional identification of early renal function loss in older adults with preserved renal function.
The Kidney Disease Improving Global Outcomes guidelines recommend that clinical laboratories report eGFR by serum creatinine in adults, and to use either serum cystatin C-based eGFR or mGFR as a confirmatory test if a more accurate assessment is required for clinical decision making. 2 Although the CKD-EPI equations have demonstrated better accuracy than MDRD when GFR >60 ml/min per 1.73 m 2 , 6,12,50 both sets of equations are still routinely applied in research and clinical practice across adult populations. One recent study evaluated the use of cystatin C to confirm a CKD diagnosis in a primary care cohort of older adults and demonstrated that eGFR by cystatin C did not result in a significant reduction of CKD diagnosis, did not improve risk prediction, and was associated with increased cost. 51 Similarly, another study demonstrated that declines in mGFR over a 2-year period did not show enhanced association with risk of ESRD, cardiovascular events, or death compared with eGFR by creatinine. 52 In the current study of eGFR accuracy, MDRD and CKD-EPI cr had similar, but poor performance, whereas cystatin C-based eGFR had greater bias and lower accuracy, and misclassified a larger proportion of the participants into different, clinically significant, GFR range subgroups. The evaluation of the novel b2M equation did demonstrate stronger operating characteristics than creatinine-and cystatin Cbased eGFR with respect to bias, but its usefulness was limited by a lack of precision and accuracy.
Importantly, the MDRD, CKD-EPI, and b2M equation development studies were limited in their inclusion of older adults in both internal derivation and external validation datasets. 5, 6, 18 These limitations support the concerns raised by the findings of the current study: current eGFR equations are not accurate or precise in older adults with preserved renal function.
Strengths of our study include use of a unique cohort of older adults with and without T1D, measurement of creatinine, cystatin C, and b2M using standardized assays, performance of an inulin clearance during a euglycemic clamp after maintaining a standard diet for a week subsequent to washing out antihypertensive medications, and extensive statistical analyses including agreement estimates, performance metrics, and 95% confidence intervals for testing performance of eGFR in the overall cohort and subgroups defined by demographic and clinical characteristics. However, this study has limitations. First, none of the study participants had mGFR <60 ml/min per 1.73 m 2 and we were therefore not able to evaluate eGFR performance in older adults with CKD. Second, the study recruited participants with $50 years of T1D, and there is a potential incidence-prevalence (survivorship) bias toward exclusion of participants with more severe complications. Third, our study population was primarily white (90%) and our results may not extend to other ethnic groups. Fourth, eGFR equations were generated from 125 I-iothalamate data, 5, 6 rather than inulin clearance, which may in part explain the inaccuracy and imprecision we observed between eGFR and mGFR. Finally, although 2 clearance measures were used calculate eGFR and mGFR according to reference standard methods, they are susceptible to measurement error, which may in part explain inaccuracy and imprecision.
In conclusion, eGFR by serum creatinine, cystatin C, and b2M did not accurately or precisely ascertain GFR in older adults with and without T1D who had preserved renal function according to mGFR. Cystatin C had lower performance than creatinine as a filtration marker of GFR and had lower performance in older subgroups, and the combination of both markers did not outperform creatinine alone. The novel b2M equation did demonstrate stronger operating characteristics than creatinine-and cystatin C-based eGFR with respect to bias, but was limited by a lack of precision and accuracy and had lower performance in T1D. For clinical care, greater bias and lower accuracy at higher GFR ranges may hinder the ability to detect early phenotypes of kidney disease in older adults when interventions may be most effective and may lead to false-positive identification of CKD. Better estimates of GFR are needed for research and clinical practice in older adults, an important subgroup of the population who are at greater risk for development of CKD and its sequelae, and for whom accurate classification of renal function is essential for clinical care. We acknowledge the contributions of the Steven and Ofra Menkes Fund for supporting aspects of this research. All authors were involved in revising the manuscript critically for important intellectual content and for final approval of the version to be published. DZIC and BAP are co-senior authors. DS contributed to conception and design of the study, acquisition of data, analysis and interpretation of data, and wrote the manuscript. PB, LEL, and JAL contributed to conception and design of the study, and analysis and interpretation of the data. VL, GB, MAF, YL, and AO contributed to acquisition of data. AW, HAK, MHB, NP, and VB contributed to analysis and interpretation of data. DZIC and BAP contributed to conception and design of the study, and analysis and interpretation of data. BAP is the guarantor of this work, as such, had full access to all the data in the study and takes responsibility for the integrity and accuracy of the data and analysis.
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